Stockscreener 앱 받기
0.9627
2.81%
-0.0278
시간 외 거래:
.98
0.0173
+1.80%
전일 마감가:
$0.9905
열려 있는:
$1
하루 거래량:
681.40K
Relative Volume:
0.67
시가총액:
$122.51M
수익:
-
순이익/손실:
$-57.09M
주가수익비율:
-2.1313
EPS:
-0.4517
순현금흐름:
$-51.43M
1주 성능:
-0.34%
1개월 성능:
+9.24%
6개월 성능:
-75.38%
1년 성능:
+17.10%
1일 변동 폭
$0.9617
$1.04
1주일 범위
$0.90
$1.04
52주 변동 폭
$0.7752
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
명칭
Nautilus Biotechnology Inc
전화
206-333-2001
주소
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.9627 | 126.05M | 0 | -57.09M | -51.43M | -0.4517 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-06-27 | 개시 | Guggenheim | Buy |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2022-01-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-02 | 개시 | Cowen | Outperform |
| 2021-08-04 | 개시 | Goldman | Neutral |
| 2021-07-13 | 개시 | Jefferies | Buy |
모두보기
Nautilus Biotechnology Inc 주식(NAUT)의 최신 뉴스
Nautilus Biotechnology, Inc. SEC Filing (Sep 21, 2026) - Stock Titan
Nautilus Biotechnology details Iterative Mapping for tau proteoform profiling in new video - Traders Union
Nautilus Biotechnology Establishes New At-The-Market Offering - The Globe and Mail
Andreessen Horowitz stake in Nautilus (NASDAQ: NAUT) falls below 5% - Stock Titan
Nautilus Biotechnology May Offer Up To $300 Million Of SecuritiesSEC Filing - TradingView
Nautilus Biotechnology Launches $125 Million ATM Program With TD Cowen; Agent Fee Up to 3% - TradingView
Nautilus Biotechnology (NASDAQ: NAUT) lines up new $300M fundraising capacity - Stock Titan
Nautilus Biotechnology Files $300 Million Shelf Registration - Yahoo Finance
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms - Investing News Network
Nautilus Biotechnology paper on tau proteoform analysis published in Nature Methods - Traders Union
Nautilus found 130 forms of a protein linked to Alzheimer’s. Some appeared in just 0.1% of samples. - Stock Titan
Nautilus Biotechnology (NAUT) Advances 3.81% to $0.96, Testing Move Toward Key $1.01 ResistanceWyckoff Accumulation - dars.gov.et
Nautilus Biotechnology heads to HUPO 2026 to unveil Voyager platform breakthroughs - Traders Union
Andreessen Horowitz sells Nautilus (NAUT) shares around $1 - Stock Titan
Nautilus (NAUT) Q2 2026 Results: EPS Exceeds Its Estimate for the Current Session; Trading Move: The Stock Records a 0.69% Increase at the ClosePre-Announcement Alert - dars.gov.et
Nautilus (NAUT) Market: Finishes 8.30% Down at $0.88 in the Latest Session; Price Levels: the Session Ends Within the Reported Technical BoundariesValue Area Low - vinanet.vn
Nautilus (NAUT) Financial Results: Profit Per Share Surpasses Its Benchmark in the Current Update; Trading Move - vinanet.vn
Nautilus Biotechnology urges new methods to address biological validation challenge in proteomics - Traders Union
Nautilus (NAUT) Watch: Closes 5.82% Higher at $0.90; Technical View: Traders Can Monitor the $0.85-$0.95 Range for the Current SessionSystematic Flow - vinanet.vn
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest - MarketBeat
Nautilus Biotechnology Earnings Call Balances Promise and Risk - TipRanks
NAUT Q2 2026 Earnings: Narrower Loss Surprise Lifts Shares 22%Earnings Deceleration Risk - vinanet.vn
Perceptive Advisors group reports 9.1% Nautilus (NAUT) ownership in updated 13D/A - Stock Titan
Nautilus Biotechnology (NAUT) Slides 3.9% to $0.86, Approaching Key Support LevelLiquidity Order Flow - vinanet.vn
Nautilus Biotechnology (NAUT) Steadies Near $0.89 as Support HoldsMonthly Profile - careplusvn.com
Nautilus Biotechnology Inc (NASDAQ: NAUT) Share Price, NAUT Stock News, NAUT Share Price & Updates - Kalkine
Nautilus Biotechnology (NAUT) Institutional Ownership 2026 - MarketBeat
Nautilus Biotechnology unveils new proteomics approach for dementia studies - Traders Union
Nautilus Biotechnology: A Contrarian Proteoformics Play After Recent Pullback (NAUT) - Seeking Alpha
Nautilus Biotechnology, Inc. Revenue Breakdown – NASDAQ:NAUT - TradingView
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Rises By 74.6% - MarketBeat
Nautilus Biotechnology sets 31 July deadline for Iterative Mapping Grant Program applications - tradersunion.com
Nautilus Biotechnology Inc (NAUT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nautilus Biotechnology, Inc. 2026: Revenue $190K, EPS ($0.11) — 10-Q Summary - tradingview.com
Nautilus Biotechnology Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Nautilus Biotechnology beats Q2 2026 EPS forecast - Investing.com
Nautilus Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Nautilus Biotechnology posts first revenue, Q2 net loss narrows - TradingView
Nautilus Biotechnology (NASDAQ: NAUT) shifts roadmap after Q2 2026 results - Stock Titan
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results - Yahoo Finance
Nautilus Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NAUT|Nautilus Biotechnology Inc|Price:0.977|Chg%:-0.053 - TradingKey
Nautilus Biotechnology reports Q2 2026: $0.2M revenue, $14.5M net loss, $129.2M cash - TradingView
Nautilus Biotechnology Reports $190,000 Revenue in Second Quarter 2026 - Quiver Quantitative
Price to earnings forward of Nautilus Biotechnology, Inc. – NASDAQ:NAUT - TradingView
Nautilus Biotechnology Inc (NAUT) Cash Flow - TradingKey
Nautilus Biotechnology Inc (NAUT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NAUT|Nautilus Biotechnology Inc|Price:1.690|Chg%:-0.080 - TradingKey
Nautilus Biotechnology Inc (NAUT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NAUT|Nautilus Biotechnology Inc|Price:0.980|Chg%:-0.005 - TradingKey
Nautilus Biotechnology Inc (NAUT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nautilus Biotechnology Inc (NAUT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):